术后腹腔温热灌注化疗联合静脉化疗治疗进展期胃癌

Analysis on the Efficacy of Postoperative Intraperitioneal Hyperthermic Chemoperfusion Combined with Intravenous Chemotherapy for Advanced Gastric Cancer Patients

【目的】比较分析进展期胃癌术后腹腔温热灌注化疗联合静脉化疗与单纯静脉化疗的临床疗效。【方法】将70例进展期胃癌术后患者按随机原则分为治疗组（腹腔灌注化疗＋静脉化疗组，35例）及对照组（单纯静脉化疗组，35例），比较两组患者的不良反应及近、远期疗效。【结果】两组1年生存率及腹腔外脏器转移率相比较差异无统计学意义（P〉0．05），而治疗组3年、5年生存率及无瘤生存率高于对照组（P〈0．05），Ⅱ度以上胃肠道反应、肝肾功能损害及骨髓抑制等化疗副反应均低于对照组，两者差异有统计学意义（P〈0．05），治疗组腹部隐痛发生率显著高于对照组（P〈0．05）。【结论】腹腔温热灌注化疗联合静脉化疗可延长进展期胃癌术后患者生存期，降低胃肠道反应、骨髓抑制、肝肾功能损害等不良反应的发生率，而不增加腹腔外器官转移率。

[Objective] To evaluate the efficacy of postoperative intraperitoneal hyperthermic chemoperfusion （IHCP） combined with intravenous chemotherapy for advanced gastric cancer. [Methods]Seventy postoperative advanced gastric canter patients were divided into two groups randomly. Thirty five patients in treatment group received IHCP combined with intravenous chemotherapy and 35 patients in control group received only intravenous chemotherapy. [Results]There were not marked differences between the two groups in 1-year survival rate and metastasis rate of ex-abdominal organs（ P 〉0.05）, whereas the 3-year survival rate and 5-year survival rate were higher in treatment group than those in control group（ P 〈0.05）, and the incidence of gastrointestinal reaction, the function damage of liver and kidney and bone marrow suppression were lower in treatment group than those in the control group（ P 〈0.05） [Conclusion]IHCP combined with intravenous chemotherapy can prolong survival rate of advanced gastric patients and reduce gastrointestinal side effect, bone marrow suppression and the damage of liver and kidney, and do not increase the metastasis rate of ex-abdominal organs.